Chihuri Stanford, Li Guohua
1Center for Injury Epidemiology and Prevention, Columbia University Irving Medical Center, 622 West 168th St, PH5-505, New York, NY 10032 USA.
2Department of Anesthesiology, Columbia University College of Physicians and Surgeons, 622 West 168th St, PH5-505, New York, NY 10032 USA.
Inj Epidemiol. 2019 Sep 2;6:38. doi: 10.1186/s40621-019-0213-z. eCollection 2019.
The opioid epidemic in the United States is a national public health crisis. In recent years, marijuana legalization has been increasingly adopted by state governments as a policy intervention to control the opioid epidemic under the premise that marijuana and opioids are substitutive substances. The purpose of this systematic review is to synthesize the empirical evidence regarding the impact of state marijuana laws on opioid overdose mortality and other opioid-related health outcomes.
A comprehensive search of the research literature in 18 bibliographic databases returned 6640 records, with 5601 abstracts reviewed, 29 full text articles screened for eligibility, and 16 eligible studies included in the systematic review. Comprehensive Meta-Analysis software was used to generate summary estimates, forest plots, funnel plots, and heterogeneity statistics.
Of the 16 eligible studies, 4 assessed the association of state marijuana law status with opioid overdose mortality, 7 with prescription opioids dispensed, and the remaining with nonmedical use and opioid-related hospitalizations. Random effects modeling based on pooled data revealed that legalizing marijuana for medical use was associated with a statistically non-significant 8% reduction in opioid overdose mortality (95% confidence interval: - 0.21 to 0.04; = 0.201) and a 7% reduction in prescription opioids dispensed (95% confidence interval: - 0.13 to - 0.01; = 0.017). Legalizing marijuana for recreational use was associated with an additional 7% reduction in opioid overdose mortality in Colorado and 6% reduction in opioid prescriptions among fee-for-service Medicaid and managed care enrollees.
Legalizing marijuana might contribute to a modest reduction in opioid prescriptions. Evidence about the effect of marijuana legalization on opioid overdose mortality is inconsistent and inconclusive. If any, the effectiveness of state marijuana laws in reducing opioid overdose mortality appears to be rather small and limited to states with operational marijuana dispensaries. It remains unclear whether the presumed benefit of legalizing marijuana in reducing opioid-related harms outweighs the policy's externalities, such as its impact on mental health and traffic safety.
美国的阿片类药物泛滥是一场全国性的公共卫生危机。近年来,州政府越来越多地采用大麻合法化作为一种政策干预措施,在大麻与阿片类药物是替代物质这一前提下控制阿片类药物泛滥。本系统评价的目的是综合关于州大麻法律对阿片类药物过量死亡率及其他与阿片类药物相关的健康结果影响的实证证据。
在18个文献数据库中对研究文献进行全面检索,共获得6640条记录,其中5601篇摘要被审阅,29篇全文文章经筛选符合纳入标准,16项符合条件的研究被纳入该系统评价。使用综合荟萃分析软件生成汇总估计值、森林图、漏斗图和异质性统计数据。
在16项符合条件的研究中,4项评估了州大麻法律状况与阿片类药物过量死亡率之间的关联,7项评估了与处方阿片类药物配给量之间的关联,其余研究评估了与非医疗用途及与阿片类药物相关的住院治疗之间的关联。基于汇总数据的随机效应模型显示,医用大麻合法化与阿片类药物过量死亡率在统计学上无显著意义的8%降低相关(95%置信区间:-0.21至0.04;P = 0.201),以及处方阿片类药物配给量7%的降低(95%置信区间:-0.13至-0.01;P = 0.017)。娱乐用大麻合法化与科罗拉多州阿片类药物过量死亡率额外降低7%以及按服务收费的医疗补助和管理式医疗参保者的阿片类药物处方量降低6%相关。
大麻合法化可能有助于适度减少阿片类药物处方量。关于大麻合法化对阿片类药物过量死亡率影响的证据并不一致且尚无定论。如果有影响的话,州大麻法律在降低阿片类药物过量死亡率方面的有效性似乎相当小,且仅限于有运营中的大麻药房的州。大麻合法化在减少与阿片类药物相关危害方面假定的益处是否超过该政策的外部影响,如对心理健康和交通安全的影响,仍不清楚。